Kiniksa Pharmaceuticals International, plc - KNSA STOCK NEWS

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a public offering of $100 million in Class A common shares, with an option for underwriters to purchase an additional $15 million. The proceeds will be used to advance product development and commercialization, as well as for general corporate purposes. Goldman Sachs, BofA Securities, and J.P. Morgan are acting as joint book-running managers. The registration statement for this offering was declared effective on June 10, 2019. Investors should review the prospectus for more information.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) announced that the FDA granted Orphan Drug designation for rilonacept to treat pericarditis, including recurrent forms. This treatment, which is injected weekly, blocks two signaling proteins, IL-1α and IL-1β. The company plans to submit a supplemental Biologics License Application (sBLA) for recurrent pericarditis later in 2020, following positive Phase 3 trial results from RHAPSODY, which met all primary and secondary endpoints. The Orphan Drug status offers financial incentives and exclusivity for seven years upon approval.

Kiniksa Pharmaceuticals (KNSA) reported positive results from RHAPSODY, a pivotal Phase 3 trial of rilonacept for recurrent pericarditis. The trial met its primary and all major secondary efficacy endpoints, showing a 96% reduction in recurrence risk (Hazard Ratio = 0.04, p<0.0001). The safety profile aligns with FDA-approved uses for CAPS. Kiniksa plans to submit a Supplemental Biologics License Application (sBLA) later this year. Rilonacept is positioned to potentially become the first FDA-approved treatment for recurrent pericarditis, addressing significant unmet medical needs.

Kiniksa Pharmaceuticals (KNSA) announced a presentation at the European E-Congress of Rheumatology (EULAR) 2020 on June 3, 2020, showcasing data on mavrilimumab, an investigational monoclonal antibody for severe COVID-19 pneumonia and hyperinflammation. The oral presentation will detail outcomes from an open-label treatment protocol conducted in Italy, while additional preclinical data on the GM-CSF pathway in giant cell arteritis will be presented on June 5. Mavrilimumab has previously met its primary efficacy and safety endpoints in Phase 2b studies for rheumatoid arthritis.

Kiniksa Pharmaceuticals (KNSA) has closed a public offering of 2,760,000 Class A common shares at $18.25 each, raising approximately $80 million in gross proceeds. This includes the complete exercise of the underwriters' option to purchase additional shares. The offering was managed by Goldman Sachs, J.P. Morgan, and BofA Securities, with co-management by Wedbush Securities and JMP Securities. Kiniksa focuses on developing therapeutic medicines for serious diseases, with a clinical pipeline including rilonacept, mavrilimumab, vixarelimab, and KPL-404 targeting immunological pathways.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced a public offering of 2,400,000 Class A common shares, priced at $18.25 each, alongside a private placement of 1,600,000 shares. The total expected gross proceeds from both offerings is approximately $73 million. The funds will be used to advance clinical development and for general corporate purposes. The public offering is set to close on May 18, 2020, subject to standard conditions. The underwriters have a 30-day option to purchase an additional 360,000 shares.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a public offering of 1,800,000 Class A common shares, with an additional 270,000 shares available to underwriters. The net proceeds will support the clinical development of its product candidates, fund R&D activities, and cover general corporate purposes. Goldman Sachs, J.P. Morgan, and BofA Securities are managing the offering. Kiniksa emphasizes that the offering's details are included in the SEC registration statement, which should be reviewed before investing.

The press release from Kiniksa Pharmaceuticals, Ltd. highlights positive clinical results from two investigational treatments: mavrilimumab and vixarelimab. Mavrilimumab demonstrated improved outcomes in severe COVID-19 pneumonia patients, with 85% achieving clinical improvement by day 14, significantly outperforming the control group. Vixarelimab showed promising efficacy in chronic pruritus diseases, particularly plaque psoriasis, achieving a statistically significant reduction in itch severity. Kiniksa plans further development for both drugs, including potential registrational studies for mavrilimumab.